))
The Outlook for Controlled Substances in 2025
Manage episode 466205937 series 3528724
Content provided by Ropes & Gray LLP and Gray LLP. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ropes & Gray LLP and Gray LLP or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
On this episode of Ropes & Gray’s podcast series Controlling Opinions, life sciences regulatory and compliance partner Josh Oyster and counsel Beth Weinman are joined by health care partner Brett Friedman and litigation and enforcement partner Andrew O’Connor to discuss what’s to come in 2025 under the new Trump administration on key issues relating to controlled substances. The discussion covers:
- The DEA’s potential rescheduling of cannabis and the ongoing administrative hearing process.
- Updates on telemedicine flexibilities for prescribing controlled substances, including new rules and proposed regulations.
- Latest enforcement developments from the DOJ related to controlled substance prescribing via telemedicine, including notable cases and implications for the future.
Tune in for an insightful conversation on these critical topics and stay informed about the latest legal and regulatory changes in the life sciences and health care industries.
5 episodes
Share
